La Jolla, California, U.S.

Devin Sok Web croppedThe IAVI Neutralizing Antibody Center is a principal source of innovation worldwide in the study of bnAbs and the design of immunogens that could elicit HIV bnAbs in the human body.

IAVI’s Neutralizing Antibody Center (NAC) was established in 2002, and today, is a leading source of innovation in the study of broadly neutralizing antibodies (bnAbs) and the design of immunogens to elicit these antibodies through vaccination. The NAC brings together leading investigators — including structural and computational biologists, immunologists, protein chemists, and glycobiologists — from institutions worldwide.

During the past decade, through the efforts of the NAC and many other leading scientific collaborators, more than 200 HIV-specific bnAbs have been isolated from volunteers around the world. The structures of some of the most potent of these antibodies and their targets have also been solved. These discoveries are now guiding the design of novel HIV vaccine candidates designed to induce bnAbs. Some of these antibodies are also being developed as potential HIV prevention products.

The NAC is headquartered at Scripps Research in La Jolla, California. The NAC’s principal investigators are:

  • Dennis Burton, scientific director, NAC; chair of the Department of Immunology and Microbiology, Scripps Research
  • Bill Schief, director of vaccine design, NAC; professor, Department of Immunology and Microbiology, Scripps Research
  • Devin Sok, director, antibody discovery and development, IAVI
  • Andrew Ward, professor, Department of Integrative Structural and Computational Biology, Scripps Research
  • Ian Wilson, Hansen Professor of Structural Biology and chairman, Department of Integrative Structural and Computational Biology, Scripps Research
  • Rich Wyatt, senior director, viral immunology, NAC


Selected publications by NAC investigators and their collaborators:

Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies. PLoS Pathog 12(8): e1005767. 2016. (Open access)

High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Rep 15(9): 1986-1999. 2016. (Open access)

Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351(6277): 1043-1048. 2016. (Subscription required)

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. Cell Rep 16(9): 2327-2338. 2016. (Open access)

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity 45(1): 31-45. 2016. (Open access)

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 45(3): 483-496. 2016. (Open access)

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. Cell 166(6): 1445-1458 e1412. 2016. (Open access)

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351(6280): 1458-1463. 2016. (Open access)

Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. PLoS Pathog 12(8): e1005815. 2016. (Open access)

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell 166(6): 1459-1470 e1411. 2016. (Open access)

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell 166(6): 1471-1484 e1418. 2016. (Open access)

Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353(6307): 1557-1560. 2016. (Open access)

Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature 548(7665): 108-111. 2017. (Open access)


Further Reading

Our bnAb Discoveries

A New Generation of Vaccine Candidates